Press Releases

All Releases
Nektar Therapeutics Reports Financial Results for the First Quarter of 2016
May 3, 2016
PDF 33.1 KB
Nektar to Announce Financial Results for the First Quarter 2016 on Tuesday, May 3, 2016, After Close of U.S.-Based Financial Markets
Apr 28, 2016
PDF 9.9 KB
Preclinical Data Presented at AACR Demonstrate that Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition in Increasing Clonality of the T Cell Receptor (TCR) Repertoire and T Cell Tumor Infiltration
Apr 18, 2016
PDF 60.3 KB
Baxalta Expands Global Reach of ADYNOVATE for Hemophilia A Patients with Approval in Japan
Apr 4, 2016
PDF 72.9 KB
Nektar Therapeutics to Present at Cowen and Company's 36th Annual Health Care Conference in Boston, MA
Mar 3, 2016
PDF 8.8 KB
Nektar Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results
Mar 1, 2016
PDF 36.3 KB
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2015 on Tuesday, March 1, 2016, After Close of U.S.-Based Financial Markets
Feb 26, 2016
PDF 10.4 KB
Baxalta Announces Submission of Supplemental BLAs to Expand Use of ADYNOVATE to Pediatric Patients and Surgical Settings
Feb 25, 2016
PDF 21.6 KB
Nektar Publishes Pre-clinical Results for NKTR-214, an Investigational CD122-Biased Immune-Stimulatory Cytokine for the Treatment of Cancer in Clinical Cancer Research
Feb 1, 2016
PDF 17.9 KB
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Jan 6, 2016
PDF 9.4 KB
Nektar Therapeutics to Present at Oppenheimer 26th Annual Healthcare Conference in New York
Dec 8, 2015
PDF 7.2 KB
Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine
Dec 8, 2015
PDF 14.4 KB
Baxalta Presents Additional Data on Newly-Approved ADYNOVATE and Plans for New Indications During 57th American Society of Hematology (ASH) Annual Meeting
Dec 7, 2015
PDF 92.2 KB
Baxalta Announces U.S. Availability of ADYNOVATE, A New Treatment for Adult Patients with Hemophilia A With a Simple, Twice-Weekly Dosing Schedule
Nov 30, 2015
PDF 64.8 KB
Nektar Therapeutics to Present at Jefferies Autumn 2015 Global Healthcare Conference in London
Nov 17, 2015
PDF 8.4 KB
Baxalta to Advance Care for Hemophilia A patients with FDA Approval of ADYNOVATE, a Simple, Twice-weekly Treatment to Reduce Bleeds
Nov 16, 2015
PDF 67.9 KB
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015
Nov 5, 2015
PDF 28.8 KB
Nektar to Announce Financial Results for the Third Quarter 2015 on Thursday, November 5, 2015, After Close of U.S.-Based Financial Markets
Oct 29, 2015
PDF 10.0 KB
Nektar Reports on Advancements with Pain and Oncology Clinical Pipeline at Investor and Analyst R&D Day
Oct 8, 2015
PDF 13.5 KB
Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies
Oct 7, 2015
PDF 15.5 KB
Showing 1-20 of 247 Page: 1 2 3 ... 13  Next 20
 
 
Site Map Privacy Terms of Use Trademarks Site Users Guide